Basilea names new member of its Extended Management Committee
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea names new member of its Extended Management Committee
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, June 2, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced that, as of August 1, 2017, Damian Heller will assume the role of
General Counsel & Corporate Secretary and join the Extended Management Committee
which reports to the CEO. Mr. Heller succeeds Elizabeth Rozek who will be
leaving Basilea to relocate to the United States.
Mr. Heller joined Basilea in 2015 as Deputy General Counsel and Global
Compliance Officer. Prior to joining Basilea, he served as Global Compliance
Officer at Novartis Pharma AG, Corporate Secretary of Syngenta AG and Director
of the Basel Institute on Governance.
Mr. Heller holds a master's degree in Law from the University of Basel and a
master's degree in Business Administration from the University of Rochester, New
York, USA.
Ronald Scott, Basilea's Chief Executive Officer, commented: "We are very pleased
that Mr. Heller will assume the role of General Counsel & Corporate Secretary.
Damian's knowledge and broad experience in all aspects of pharmaceutical
industry law and compliance will be an asset to Basilea. Ms. Rozek joined
Basilea as counsel in 2010 and has served as General Counsel & Corporate
Secretary since 2011. We wish to sincerely thank Elizabeth for her commitment
and valuable contributions to Basilea's success during these years."
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address the medical problem of increasing resistance and non-response to
current treatment options in the therapeutic areas of bacterial infections,
fungal infections and cancer. The company uses the integrated research,
development and commercial operations of its subsidiary Basilea Pharmaceutica
International Ltd. to discover, develop and commercialize innovative
pharmaceutical products to meet the medical needs of patients with serious and
potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is
headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX:
BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+-------------------------------------------------------+
| Peer Nils Schröder, PhD |
| Head of Corporate Communications & Investor Relations |
| +41 61 606 1102 |
| media_relations(at)basilea.com |
| investor_relations(at)basilea.com |
+-------------------------------------------------------+
This press release can be downloaded from www.basilea.com.
Press release (PDF):
http://hugin.info/134390/R/2110032/801866.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.06.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 545964
Anzahl Zeichen: 4443
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea names new member of its Extended Management Committee"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
